Borghese Martina, Vizzielli Giuseppe, Capelli Giovanni, Santoro Angela, Angelico Giuseppe, Arciuolo Damiano, Biglia Nicoletta, Ferrero Annamaria, Sgro Luca Giuseppe, Ponzone Riccardo, Scambia Giovanni, Fagotti Anna, Zannoni Gian Franco
Department of Obstetrics and Gynecology, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy
Department of Medical Area (DAME), University of Udine, Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital - Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Int J Gynecol Cancer. 2022 Sep 6;32(9):1171-1176. doi: 10.1136/ijgc-2022-003468.
Primary fallopian tube carcinoma represents a rare entity, accounting for about 0.75%-1.2% of all gynecological malignancies. The rationale of our study is to describe the prognosis of primary fallopian tube carcinoma.
We retrospectively identified patients with FIGO stage I-IV, all histology types and grading primary fallopian tube carcinoma treated in three major oncological centers between January 2000 and March 2020. Exclusion criteria were bulky tubo-ovarian carcinomas, isolated serous tubal intraepithelial carcinoma or neoadjuvant chemotherapy.
A total of 61 patients were included. The vast majority of primary fallopian tube carcinomas were serous (96.7%) and poorly differentiated (96.7%) and arose from the fimbriated end of the tube (88.5%). Larger tumor size correlated with higher probability of correct preoperative differential diagnosis of primary fallopian tube carcinoma (p=0.003). Up to 82.4% of patients with small tumors (≤15 mm) presented with high FIGO stage (≥IIA). The most common site of metastasis was pelvic peritoneum (18.8%) and among 59% of patients who underwent lymphadenectomy smaller tumors had higher rate of nodal metastasis (42.9%≤10 mm vs 27.3%>50 mm). After 46.0 months of mean follow-up there were 27 recurrences (48.2%). The most common site of relapse was diffuse peritoneal spread (18.5%). The 5-year disease-free survival was 45.2% and 5-year overall survival was 75.5%. Of note, 42.9% of patients with stage IVB survived >36 months.
Primary fallopian tube carcinoma is a biologically distinct tumor from primary epithelial ovarian carcinoma and it is mostly located in the fimbriated end of the tube. In addition, it is characterized by a high rate of retroperitoneal dissemination even at apparently an early stage and its size does not correlate with FIGO stage at presentation.
原发性输卵管癌是一种罕见的疾病,约占所有妇科恶性肿瘤的0.75%-1.2%。我们研究的目的是描述原发性输卵管癌的预后情况。
我们回顾性地确定了2000年1月至2020年3月期间在三个主要肿瘤中心接受治疗的FIGO I-IV期、所有组织学类型和分级的原发性输卵管癌患者。排除标准为巨大的输卵管卵巢癌、孤立的浆液性输卵管上皮内癌或新辅助化疗。
共纳入61例患者。绝大多数原发性输卵管癌为浆液性(96.7%)且分化差(96.7%),起源于输卵管伞端(88.5%)。肿瘤体积越大,术前正确诊断原发性输卵管癌的可能性越高(p=0.003)。高达82.4%的小肿瘤(≤15 mm)患者表现为高FIGO分期(≥IIA)。最常见的转移部位是盆腔腹膜(18.8%),在接受淋巴结清扫术的59%患者中,较小肿瘤的淋巴结转移率更高(≤10 mm者为42.9%,>50 mm者为27.3%)。平均随访46.0个月后,有27例复发(48.2%)。最常见的复发部位是弥漫性腹膜播散(18.5%)。5年无病生存率为45.2%,5年总生存率为75.5%。值得注意的是,IVB期患者中有42.9%存活超过36个月。
原发性输卵管癌在生物学上与原发性上皮性卵巢癌不同,且大多位于输卵管伞端。此外,其特点是即使在明显早期也有较高的腹膜后播散率,其大小与就诊时的FIGO分期无关。